Structure via PubChem · Public domain (PubChem)
garenoxacin
Sign in to saveAlso known as T-3811, T 3811, BMS-284756, BMS284756, BMS 284756, desquinolone
Garenoxacin (INN) is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.
Chemical data
- Formula
- C23H20F2N2O4
- Molecular weight
- 426.4 g/mol
- IUPAC name
- 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid
- SMILES
- C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F
- InChIKey
- NJDRXTDGYFKORP-LLVKDONJSA-N
- XLogP
- 2.1
- Polar surface area
- 78.9 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2007
- Indications
- bacterial disease
via ChEMBL · EBI
Research
290 papers- Clinical studies of garenoxacin.International journal of antimicrobial agents · 2008
- Garenoxacin.The Journal of the Association of Physicians of India · 2014
- Garenoxacin pharmacokinetics in subjects with renal impairment.Current medical research and opinion · 2007
- Garenoxacin pharmacokinetics in patients undergoing maintenance hemodialysis.Hemodialysis international. International Symposium on Home Hemodialysis · 2017
- The clinical efficacy of garenoxacin for male non-gonococcal urethritis.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2020
via PubMed
Wikidata facts
- Mass
- 426.139
- Has use
- medication
Show 4 more facts
- chemical formula
- C₂₃H₂₀F₂N₂O₄
- canonical SMILES
- CC1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F
- isomeric SMILES
- C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F
- World Health Organisation international non-proprietary name
- garenoxacin
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Garenoxacin (INN) is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.
Garenoxacin was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for garenoxacin, except for Japan, South Korea, and China.
Excerpted from Wikipedia’s “garenoxacin” article, available under the CC BY-SA 4.0 licence.
Available in 8 languages
via Wikidata sitelinks · CC0